TSLA
Tesla
-- 454.130 NVDA
NVIDIA
-- 139.930 RGTI
Rigetti Computing
-- 15.4400 LAES
SEALSQ Corp
-- 8.760 PLTR
Palantir
-- 82.140 
Update
$Senseonics (SENS.US)$ Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
25 MINUTES AGO, 4:05 PM EDT
VIA GLOBENEWSWIRE
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older
Commercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year
GERMANTOWN, Md. and ST. LOUIS, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) ("Senseonics" or the "Company"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system. This milestone, part of the company's previously announced collaboration with Mercy, marks the world's first commercial use of Eversense 365, the only CGM to provide one-year of accurate monitoring with minimal interruptions.
25 MINUTES AGO, 4:05 PM EDT
VIA GLOBENEWSWIRE
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older
Commercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year
GERMANTOWN, Md. and ST. LOUIS, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) ("Senseonics" or the "Company"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system. This milestone, part of the company's previously announced collaboration with Mercy, marks the world's first commercial use of Eversense 365, the only CGM to provide one-year of accurate monitoring with minimal interruptions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
萬軍無兵策天鳳 : Without the start of sales and good sales data, it feels difficult to drive the stock price.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP 萬軍無兵策天鳳 : Agreed! Hehehe! I do hate when companies release what could be great news and don’t put the important parts! Like a contract! But not how much it’s worth? Hehehe GL
一哭二闹三上悠亚 萬軍無兵策天鳳 : Since 2020, the current stocks are still down by 70%, so new investors should not hold large positions. After FDA approval in 90 days, there was a sharp drop on the same day, followed by a sustained decline for six months. Recently, after FDA approval in 365 days, the stocks dropped back to near the lowest point within two days. Every financial report results in explosions, CEOs frequently sell stocks, split shares, and issue new shares that are not beneficial to shareholders. Moreover, the company's products are all prescription drugs with limited sales channels and the company is heavily indebted, so it would not be surprising if it goes bankrupt one day.